


HIV-1 Solution v2

Antiretroviral therapy is subject to continuous changes and improvements whereby people currently treated for HIV live longer and have a better quality of life. HIV virus is able to replicate very quickly in the individual, introducing during the replication process, several mutations which increase the ability to replicate even during antiretroviral drug treatments, treatments against which the virus can acquire resistance. In the clinical setting, the availability of a standardized test for genotyping and evaluating HIV drug resistance, is fundamental for the success of pharmacological treatments.

TARGET REGIONS



Protease

codons 1 to 99

Integrase

codons 1 to 289

Reverse Transcriptase

codons 1 to 440


gp120

codons 266 to 366


HIV-1 Solution v2 kit is an in vitro method based on the amplification by RT-PCR of the viral RNA regions considered having a key role for the development of drug resistance (RT, Protease, Integrase and *gp120*), followed by NGS sequencing and automatic interpretation of results.



LIBRARY PREP:
RT - PROTEASE
INTEGRASE - *gp120*



SEQUENCING
NGS




AUTOMATIC
INTERPRETATION
SOFTWARE

SmartSeq
simply bioinformatics



HIV-1 KIT WORKFLOW



SEQUENCING INFORMATION

illumina® Kit	Number of samples	Sequencing Time illumina® official data
MiSeq™ Reagent Nano Kit v2 (500-cycles)	8	~ 28 h
MiSeq™ Reagent Micro Kit v2 (300-cycles)	16	~ 19 h
ISEQ™ 100 i1 Reagent (300-cycles)	16	~ 17 h

ORDERING INFORMATION

Cat. Number	Product	Package volume
AD-003-032	HIV-1 Solution v2	32 rxns